Sign In
Buy ALGS
$5.14
-0.110 (-2.10%)
At Close: Jun 03, 2026
Head to Head Review: Xilio Therapeutics (NASDAQ:XLO) and Aligos Therapeutics (NASDAQ:ALGS)
02:10am, Sunday, 04'th Jan 2026
Aligos Therapeutics (NASDAQ: ALGS - Get Free Report) and Xilio Therapeutics (NASDAQ: XLO - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 4.5% – Time to Sell?
02:13am, Tuesday, 30'th Dec 2025
Aligos Therapeutics, Inc. (NASDAQ: ALGS - Get Free Report) dropped 4.5% during trading on Monday. The stock traded as low as $9.33 and last traded at $9.65. Approximately 57,630 shares changed hands d
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 12'th Dec 2025
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving pa
Aligos Therapeutics Presents Positive Data at HEP-DART 2025
08:00am, Thursday, 11'th Dec 2025
Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists Oral presentation of ALG-055009 in vivo nonclinical data sho
Aligos Therapeutics, Inc. (ALGS) Presents at Jefferies London Healthcare Conference 2025 Transcript
07:43pm, Thursday, 20'th Nov 2025
Aligos Therapeutics, Inc. ( ALGS ) Jefferies London Healthcare Conference 2025 November 17, 2025 10:00 AM EST Company Participants Lawrence Blatt - CEO, President & Chairman of the Board Conference Ca
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 14'th Nov 2025
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving pa
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025
08:00am, Monday, 10'th Nov 2025
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-i
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
08:30am, Thursday, 06'th Nov 2025
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes thro
Aligos Therapeutics to Present at Upcoming Investor Conferences
08:30am, Tuesday, 04'th Nov 2025
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in
Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025
08:30am, Thursday, 30'th Oct 2025
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-cl
Aligos Therapeutics (NASDAQ:ALGS) Shares Down 3.6% – Here’s What Happened
02:52am, Friday, 24'th Oct 2025
Shares of Aligos Therapeutics, Inc. (NASDAQ: ALGS - Get Free Report) were down 3.6% on Thursday. The company traded as low as $9.25 and last traded at $9.49. Approximately 76,223 shares traded hands d
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:30am, Friday, 17'th Oct 2025
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving pa
Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
12:30pm, Thursday, 16'th Oct 2025
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-i
Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
08:30am, Thursday, 16'th Oct 2025
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-i
Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference
08:30am, Tuesday, 14'th Oct 2025
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-i
